WO2012064306A3 - Effervescent formulations of rosuvastatin - Google Patents

Effervescent formulations of rosuvastatin Download PDF

Info

Publication number
WO2012064306A3
WO2012064306A3 PCT/TR2011/000248 TR2011000248W WO2012064306A3 WO 2012064306 A3 WO2012064306 A3 WO 2012064306A3 TR 2011000248 W TR2011000248 W TR 2011000248W WO 2012064306 A3 WO2012064306 A3 WO 2012064306A3
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
effervescent formulations
effervescent
formulations
pharmaceutically acceptable
Prior art date
Application number
PCT/TR2011/000248
Other languages
French (fr)
Other versions
WO2012064306A2 (en
Inventor
Bilgic Mahmut
Original Assignee
Bilgic Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilgic Mahmut filed Critical Bilgic Mahmut
Publication of WO2012064306A2 publication Critical patent/WO2012064306A2/en
Publication of WO2012064306A3 publication Critical patent/WO2012064306A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to effervescent formulations comprising rosuvastatin and/or a pharmaceutically acceptable salt thereof as active agent.
PCT/TR2011/000248 2010-11-11 2011-11-03 Effervescent formulations of rosuvastatin WO2012064306A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09399 2010-11-11
TR2010/09399A TR201009399A2 (en) 2010-11-11 2010-11-11 Rapidly soluble effervescent rosuvastatin formulations.

Publications (2)

Publication Number Publication Date
WO2012064306A2 WO2012064306A2 (en) 2012-05-18
WO2012064306A3 true WO2012064306A3 (en) 2012-08-09

Family

ID=45607337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000248 WO2012064306A2 (en) 2010-11-11 2011-11-03 Effervescent formulations of rosuvastatin

Country Status (2)

Country Link
TR (1) TR201009399A2 (en)
WO (1) WO2012064306A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016042372A1 (en) 2014-09-17 2016-03-24 Steer Engineering Private Limited Effervescent composition and method of making it
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254950A2 (en) * 1997-04-14 2002-11-06 The Procter & Gamble Company Effervescence compositions and dry effervescent granules
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
US20070048375A1 (en) * 2003-12-19 2007-03-01 Wolfgang Wiehl Effervescent preparation of a basic medicinally active substance
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
US20090304602A1 (en) * 2008-06-06 2009-12-10 Tuchinsky David B Nutritional supplement
CN101618215A (en) * 2009-08-16 2010-01-06 王丽燕 Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins
WO2010030201A2 (en) * 2008-09-09 2010-03-18 Zaklady Farmaceutyczne Polpharma Sa Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
WO2011152803A1 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
WO2012064307A1 (en) * 2010-11-11 2012-05-18 Bilgic Mahmut Pharmaceutical compositions comprising rosuvastatin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254950A2 (en) * 1997-04-14 2002-11-06 The Procter & Gamble Company Effervescence compositions and dry effervescent granules
US20070048375A1 (en) * 2003-12-19 2007-03-01 Wolfgang Wiehl Effervescent preparation of a basic medicinally active substance
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
US20090304602A1 (en) * 2008-06-06 2009-12-10 Tuchinsky David B Nutritional supplement
WO2010030201A2 (en) * 2008-09-09 2010-03-18 Zaklady Farmaceutyczne Polpharma Sa Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
CN101618215A (en) * 2009-08-16 2010-01-06 王丽燕 Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins
WO2011152803A1 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin
WO2012064307A1 (en) * 2010-11-11 2012-05-18 Bilgic Mahmut Pharmaceutical compositions comprising rosuvastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 201014, Derwent World Patents Index; Class B05, AN 2010-A74002, XP002677880, WANG L: "Composition is used in form of tablets for treating e.g. heart cerebrovascular diseases related with hypertension and myocardial infarction, comprises calcium ion antagonist, angiotensin II receptor antagonist, statins, and carrier" *

Also Published As

Publication number Publication date
TR201009399A2 (en) 2012-05-21
WO2012064306A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
ZA201304858B (en) Active ingredient combinations comprising pyridylethylbenzamides and other active ingredients
IL222548A (en) Hydroxamic acid derivatives and pharmaceutical compositions and antimicrobial agents comprising the same
EP2583684A4 (en) Peptide having antimicrobial or anti-inflammatory activity and pharmaceutical composition containing same as an active ingredient
WO2012030993A3 (en) Skin compositions and methods of use thereof
WO2011093824A3 (en) Effervescent formulations comprising cefaclor
WO2012020097A3 (en) Use of binders for manufacturing storage stable formulations
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012048176A3 (en) Attachment and retention formulations for biologically active organic compounds
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
EP2612914A4 (en) Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
EP2415764A4 (en) Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012064302A3 (en) Improved montelukast formulations
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
HK1188983A1 (en) Novel dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
SI2590620T1 (en) Stable aqueous formulations comprising poorly water soluble active ingredients
HU1000565D0 (en) Process for the preparation of pharmaceutically active compound and intermediers
WO2012064306A3 (en) Effervescent formulations of rosuvastatin
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
WO2012065028A3 (en) Substituted tetracyclines
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2011042077A3 (en) Transdermal therapeutic systems containing 4-n-butylresorcinol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817550

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011817550

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 11817550

Country of ref document: EP

Kind code of ref document: A2